400 related articles for article (PubMed ID: 31169041)
1. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
[No Abstract] [Full Text] [Related]
2. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
Birault V; Solari R; Hanrahan J; Thomas DY
Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
[TBL] [Abstract][Full Text] [Related]
3. Novel pharmacological strategies to treat cystic fibrosis.
Hanrahan JW; Sampson HM; Thomas DY
Trends Pharmacol Sci; 2013 Feb; 34(2):119-25. PubMed ID: 23380248
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
Arora K; Naren AP
Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
[TBL] [Abstract][Full Text] [Related]
5. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
[TBL] [Abstract][Full Text] [Related]
6. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
8. An overview on chemical structures as ΔF508-CFTR correctors.
Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
[TBL] [Abstract][Full Text] [Related]
9. Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines.
Sampson HM; Lam H; Chen PC; Zhang D; Mottillo C; Mirza M; Qasim K; Shrier A; Shyng SL; Hanrahan JW; Thomas DY
Orphanet J Rare Dis; 2013 Jan; 8():11. PubMed ID: 23316740
[TBL] [Abstract][Full Text] [Related]
10. Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Chung WJ; Goeckeler-Fried JL; Havasi V; Chiang A; Rowe SM; Plyler ZE; Hong JS; Mazur M; Piazza GA; Keeton AB; White EL; Rasmussen L; Weissman AM; Denny RA; Brodsky JL; Sorscher EJ
PLoS One; 2016; 11(10):e0163615. PubMed ID: 27732613
[TBL] [Abstract][Full Text] [Related]
11. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.
Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V
Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489
[TBL] [Abstract][Full Text] [Related]
12. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
Yu W; Kim Chiaw P; Bear CE
J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
[TBL] [Abstract][Full Text] [Related]
13. Unravelling druggable signalling networks that control F508del-CFTR proteostasis.
Hegde RN; Parashuraman S; Iorio F; Ciciriello F; Capuani F; Carissimo A; Carrella D; Belcastro V; Subramanian A; Bounti L; Persico M; Carlile G; Galietta L; Thomas DY; Di Bernardo D; Luini A
Elife; 2015 Dec; 4():. PubMed ID: 26701908
[TBL] [Abstract][Full Text] [Related]
14. CFTR processing, trafficking and interactions.
Amaral MD; Hutt DM; Tomati V; Botelho HM; Pedemonte N
J Cyst Fibros; 2020 Mar; 19 Suppl 1():S33-S36. PubMed ID: 31680043
[TBL] [Abstract][Full Text] [Related]
15. Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators.
Estabrooks S; Brodsky JL
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936842
[TBL] [Abstract][Full Text] [Related]
16. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
Bell SC; De Boeck K; Amaral MD
Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
[TBL] [Abstract][Full Text] [Related]
17. Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.
Bongiorno R; Ludovico A; Moran O; Baroni D
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629017
[TBL] [Abstract][Full Text] [Related]
18. HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR.
Moniz S; Sousa M; Moraes BJ; Mendes AI; Palma M; Barreto C; Fragata JI; Amaral MD; Matos P
ACS Chem Biol; 2013 Feb; 8(2):432-42. PubMed ID: 23148778
[TBL] [Abstract][Full Text] [Related]
19. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi.
Farinha CM; Matos P; Amaral MD
FEBS J; 2013 Sep; 280(18):4396-406. PubMed ID: 23773658
[TBL] [Abstract][Full Text] [Related]
20. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR.
Sampson HM; Robert R; Liao J; Matthes E; Carlile GW; Hanrahan JW; Thomas DY
Chem Biol; 2011 Feb; 18(2):231-42. PubMed ID: 21338920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
